Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
The Wall Street Journal examines a $1.5 billion program supported by Italy, the U.K., Canada, Russia, Norway and the Bill & Melinda Gates Foundation that hopes "to encourage pharmaceutical companies to develop vaccines for diseases common to poor countries," which is expected to be announced Friday "on the sidelines of a meeting of top finance officials from the Group of Eight major industrial powers."
Drug maker GlaxoSmithKline (GSK) on Tuesday opened a $600 million plant in Singapore that is slated to begin producing vaccines to fight pneumonia-causing bacteria in 2011, Reuters reports.
Intercell AG has announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.
Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year.
Commonly used pneumococcal polysaccharide vaccines do not appear to be effective for preventing pneumonia, found a study by a team of researchers from Switzerland and the United Kingdom.
Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia.
Pneumococcal disease, one of the world's leading causes of death and serious illness, must be recognised as an urgent global health issue together with HIV, malaria and TB, say the UK All-Party Parliamentary Group (APPG) on Pneumococcal Disease Prevention in the Developing World in a report launching at the House of Lords today. Between 700,000 and one million children under the age of five die each year from pneumococcal disease, equivalent to malaria and more than AIDS and tuberculosis.
Although the childhood pneumococcal conjugate vaccine has been a boon in reducing the incidence invasive pneumococcal disease (IPD), the public and the medical community must not get complacent, as non-vaccine strains, some resistant to antibiotics, are on the rise, say scientists at a meeting today in Boston.
A population survey by the NSW Department of Health has revealed a number of interesting facts.
Since the approval of a vaccine against pneumococcal bacteria for young children in 2000, rates of invasive pneumococcal disease (IPD) are down significantly in all age groups, while rates of IPD caused by non-vaccine strains are modestly on the rise.
Vaccinating children younger than age 2 with the pneumococcal vaccine appears to be associated with decreased hospitalizations from pneumonia and reduced health care expenses, according to a report in the December issue of Archives of Pediatrics & Adolescent Medicine.
An international team of experts has published the first comprehensive review of evidence on pneumococcal conjugate vaccination (PCV) for children with HIV infection.
Since its addition to the list of routine immunizations in 2000, one childhood vaccine has helped prevent some pneumococcal-related illness, including pneumonia and otitis media.
A comparison of illness and death rates for 13 vaccine-preventable diseases in the U.S., before and after use of the vaccine, indicates there have been significant decreases in the number of cases, hospitalizations and deaths for each of the diseases examined, according to a study in the November 14 issue of JAMA: The Journal of the American Medical Association.
Among patients hospitalized with community-acquired pneumonia, those who had previously received the pneumococcal vaccine had a lower risk of death and admission to the intensive care unit than patients who were not vaccinated, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The number of cases of invasive pneumococcal disease (IPD) in children has fallen since the introduction of a new vaccine a year ago. Enhanced surveillance by the UK's Health Protection Agency has shown that cases of IPD caused by the seven major types of the pneumococcus bacteria which the new pneumococcal conjugate vaccine (PCV) protects against have gone down by almost 50%.
A vaccine introduced in 2000 has reduced by more than 90 percent the rate of a serious bacterial illness among young children with sickle cell disease (SCD), who are particularly susceptible to it, according to a new study that appears in the June 1 issue of Clinical Infectious Diseases and currently is available online.
Alaskan native children are experiencing increased rates of serious infections caused by strains of pneumococcal bacteria that are not covered by the current childhood pneumococcal vaccine, indicating the importance of ongoing surveillance of vaccine effectiveness, according to a study in the current issue of JAMA.
Babies in the UK will soon be given a vaccination against the pneumococcal disease meningitis as part and parcel of the standard infant immunisation package.
Up to 90 per cent of cases of invasive pneumococcal diseases (IPD) - which includes serious infections like meningitis - occur in otherwise healthy young children, according to a study published in the April issue of IJCP, the International Journal of Clinical Practice.